Primary Tumor Resection in Patients with Incurable Localized or Metastatic Colorectal Cancer: A Systematic Review and Meta‐analysis
Open Access
- 22 March 2019
- journal article
- review article
- Published by Wiley in World Journal of Surgery
- Vol. 43 (7) , 1829-1840
Abstract
Background: To assess the impact of primary tumor resection (PTR) on survival and morbidity in incurable colorectal cancer.Methods: Systematic literature review and meta‐analysis to compare PTR versus primary tumor intact (PTI).Results: Seventy‐seven studies were included, reporting on 159,991 participants (94,745 PTR; 65,246 PTI). PTR improved overall survival (hazard ratio [HR] 0.59, P < 0.0001; mean difference [MD] 7.27 months, P < 0.0001), cancer‐specific survival (HR 0.47, MD 10.80), and progression‐free survival (HR 0.76, MD 1.67). Overall survival remained significantly improved during subgroup analysis of asymptomatic patients (HR 0.69, MD 3.86), elderly patients (HR 0.46, MD 7.71), patients diagnosed after 2000 (HR 0.62, MD 7.29), patients with colon (HR 0.58, MD 6.31) or rectal (HR 0.54, MD 6.88) primary tumor, patients undergoing resection of primary tumor versus non‐resectional surgery (NRS) to treat primary tumor complications (HR 0.56, MD 8.72), and of studies with propensity score analysis (HR 0.65, MD 5.68). Overall survival per treatment strategy was: [PTI/chemotherapy] 14.30 months, [PTI/bevacizumab] 17.27 months, [PTR/chemotherapy] 21.52 months, [PTR/bevacizumab] 27.52 months. PTR resulted in 4.5% perioperative mortality and 22.4% morbidity (major adverse events 10.2%, minor 18.5%, reoperation 2.5%, intraabdominal collection/sepsis 2.2%). PTI had 21.7% morbidity (obstruction 14.4%, anemia 11.0%, hemorrhage 1.5%, perforation 0.6%, adverse events requiring surgery 15.8%). NRS resulted in 10.6% perioperative mortality and 21.7% morbidity (major 7.9%, minor 21.7%, reoperation 0.1%).Conclusions: PTR in patients with incurable colorectal cancer results in a limited improvement of survival without a significant increase in morbidity. PTR should be considered by the multidisciplinary team on an individual patient basis.Keywords
This publication has 128 references indexed in Scilit:
- Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen depositionBMC Cancer, 2014
- Surgery in asymptomatic patients with colorectal cancer and unresectable liver metastases: the authors' experienceOncoTargets and Therapy, 2013
- Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: Results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601European Journal of Cancer, 2013
- Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS - a randomised controlled multicentre trial (ISRCTN30964555)BMC Cancer, 2012
- Ten years experience of managing the primary tumours in patients with stage IV colorectal cancersInternational Journal of Surgery, 2010
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Classification of Surgical ComplicationsAnnals of Surgery, 2004
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986